Dr. Meshinchi’s clinical and research interests center around the treatment of pediatric myeloid leukemia. He is the principal investigator on ten research projects at FHCRC and Seattle Children’s, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification.
Seattle Children's Cancer and Blood Disorders Center:
4800 Sand Point Way NE, Seattle, WA 98105, USA
Get the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life
AML stories, AML clinical trials, AML 101 articles and events with AML
Thanks to our HealthTree Community for AML Sponsors: